-
-
Press release - 13/07/2023
Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…
https://www.gesundheitsindustrie-bw.de/en/article/press-release/intelligent-rubber-materials
-
-
-
-
-
-
-
-
-
-
-
-
-
Peptide-based COVID-19 vaccine - 21/04/2022
Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.
https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
-
pre-start-up company Wheyfinery - 13/04/2022
There is not much you can do with acid whey, which is why several million litres of it are disposed of every year. This is both costly and not sustainable. However, researchers at Tübingen University have shown: acid whey can be used to produce precursors for biofuels, fine chemicals and antimicrobial livestock feed additives. They have set up the pre-start-up company Wheyfinery in an endeavour to make their scalable biorefinery concept…
https://www.biooekonomie-bw.de/en/articles/news/acid-whey-valuable-raw-material-platform-chemicals-and-more
-
SolidCAR-T project - 15/03/2022
Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.
https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
-
-
-
-
-
-
-
Press release - 13/10/2021
EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
-
Website address: https://www.biooekonomie-bw.de/en/search